Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Survival Analysis of the Recurrent Epithelial Ovarian Cancer Patients Based on the Relapse Type: Multi-Institutional Retrospective Study in Armenia

Version 1 : Received: 3 January 2024 / Approved: 4 January 2024 / Online: 4 January 2024 (04:18:09 CET)

A peer-reviewed article of this Preprint also exists.

Harutyunyan, L.; Manvelyan, E.; Karapetyan, N.; Bardakhchyan, S.; Jilavyan, A.; Tamamyan, G.; Avagyan, A.; Safaryan, L.; Zohrabyan, D.; Movsisyan, N.; Avinyan, A.; Galoyan, A.; Sargsyan, M.; Harutyunyan, M.; Nersoyan, H.; Stepanyan, A.; Galstyan, A.; Danielyan, S.; Muradyan, A.; Jilavyan, G. A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia. Curr. Oncol. 2024, 31, 1323-1334. Harutyunyan, L.; Manvelyan, E.; Karapetyan, N.; Bardakhchyan, S.; Jilavyan, A.; Tamamyan, G.; Avagyan, A.; Safaryan, L.; Zohrabyan, D.; Movsisyan, N.; Avinyan, A.; Galoyan, A.; Sargsyan, M.; Harutyunyan, M.; Nersoyan, H.; Stepanyan, A.; Galstyan, A.; Danielyan, S.; Muradyan, A.; Jilavyan, G. A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia. Curr. Oncol. 2024, 31, 1323-1334.

Abstract

Background: About 200 new ovarian cancer cases per year are diagnosed in Armenia, an upper-middle-income country. This study aims to summarize the survival outcomes of relapsed ovarian cancer patients in Armenia based on the type of relapse, risk factors, and the choice of systemic treatment. Methods: A retrospective case-control study including 228 patients with relapsed ovarian cancer from 3 different institutions. Results: The median age of the patients was 55. The median follow-up from the relapse and primary diagnosis was 21 and 48 months. The incidence of platinum-sensitive relapse was 81.6% (186), while platinum-resistant relapse was seen only in 18.4% (42) patients. Median survival of the patients starting from the primary diagnosis in the platinum-sensitive compared to the platinum-resistant group was 54 versus 25 months (p < 0.001), and median survival after relapse: was 25 versus 13 months, respectively 3- and 5-year survival in these groups were: 31.2% vs. 23.8%, and 15.1% vs. 9.5%, respectively (p = 0,113). Conclusions: Overall, despite new therapeutic approaches, ovarian cancer continues to be one of the deadly malignant diseases in women, especially, in developing countries with a lack of resources, where, in fact, the main available systemic treatment for the majority of patients remains chemo-therapy. Low survival rates emphasize the urgent need for more research on this group of patients with poor outcomes.

Keywords

recurrent ovarian cancer; platinum-sensitive relapse; platinum-resistant relapse; platinum refractory relapse; targeted therapy; chemotherapy

Subject

Public Health and Healthcare, Other

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.